Andrew A. Wilson, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, University of Texas Southwestern Medical School

My laboratory research to date has focused on the design, cloning, production, and use of lentiviruses in vitro and in vivo to overexpress or knock down gene expression, particularly in alveolar macrophages and stem cell populations, and using lentiviruses to develop a gene therapy for alpha-1 antitrypsin deficiency. I have approached this problem through the manipulation of two target cell populations: hematopoietic stem cells and alveolar macrophages. Both approaches have resulted in long-term expression of human alpha-1 antitrypsin in laboratory animals. In addition to the in-vivo overexpression of alpha-1 antitrypsin, I am interested in manipulating other genes which may play a role in the pathogenesis of COPD, such as NF-kB.

A second area of interest is embryonic stem cell biology. I am working with Darrell Kotton and others in our division to study the progression of definitive endoderm to lung epithelium.

Research interests include:
-Alpha-1 antitrypsin deficiency
-gene therapy
-alveolar macrophage biology
-embryonic stem cells

Clinical interests include:
-Critical Care Medicine

Active Staff Privileges
Boston Medical Center
Pulmonary, Allergy, Sleep & Critical Care Medicine

A National iPS cell network with deep phenotyping for translational research
09/15/2016 - 06/30/2021 (Co-PI)
PI: Darrell Nelson Kotton, MD
NIH/National Center for Advancing Translational Sciences

Functional characterization of risk modifier gene MAN1B1 in patient-derived hepatocytes
07/01/2018 - 06/30/2020 (PI)
Alpha 1 Foundation

Personalized therapy for AATD-associated liver disease via IPS modeling
07/01/2015 - 06/30/2020 (PI)
NIH/National Diabetes & Digestive & Kidney Diseases

Contribution of Gain of Function Toxicity to AATD Lung Disease Pathogenesis
10/01/2018 - 09/30/2019 (PI)
Alpha 1 Foundation

CRISPR-DIRECTED Editing Of Patient-iPSCs To Determine Genetic Contributors
07/01/2016 - 06/30/2018 (PI)
Alpha 1 Foundation

Characterization of AATD iPSC Repository
05/15/2017 - 05/14/2018 (PI)
Alpha 1 Foundation

Effect of gene knockdown on susceptibility to drug toxicity
02/04/2016 - 02/03/2018 (PI)
Alnylam Pharmaceuticals, Inc.

Alpha-1 Clinical Resource Center (CRC) Research Registry
07/01/2016 - 06/30/2017 (PI)
Medical University of South Carolina Alpha 1 Foundation

Open Source CRISPR Gene Correction of PiZZ iPSCs
07/01/2015 - 06/30/2017 (PI)
Alpha 1 Foundation

Elucidation of Thyroid Hormone Signaling Mechanisms in Human Tissue
10/01/2016 - 03/31/2017 (PI)
Boston Medical Center Corporation NIH NIDDK

Showing 10 of 16 results. Show All Results

Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study
01/01/2015 - 12/31/2022 (PI)
St. Louis University Alpha-1 Foundation

ALPHA-1 Antitrypsin Deficiency Adult Clinical
01/01/2015 - 07/23/2019 (PI)
Alpha-1 Foundation

Yr Title Project-Sub Proj Pubs
2019 Thyroid Hormone Signaling in Human Hepatocytes 1R01DK117940-01A1
2018 A National iPS Cell Network with Deep Phenotyping for Translational Research 3U01TR001810-03S1 7
2018 A National iPS Cell Network with Deep Phenotyping for Translational Research 5U01TR001810-03 7
2018 Personalized therapy for AATD-associated liver disease via IPS modeling 5R01DK101501-04 2
2017 A National iPS Cell Network with Deep Phenotyping for Translational Research 5U01TR001810-02 7
2017 Personalized therapy for AATD-associated liver disease via IPS modeling 5R01DK101501-03 2
2016 A National iPS Cell Network with Deep Phenotyping for Translational Research 1U01TR001810-01 7
2016 Personalized therapy for AATD-associated liver disease via IPS modeling 5R01DK101501-02 2
2015 Personalized therapy for AATD-associated liver disease via IPS modeling 1R01DK101501-01A1 2
2014 Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity 5K08HL103771-05 3
Showing 10 of 14 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Reeves EP, Dunlea DM, McQuillan K, O'Dwyer CA, Carroll TP, Saldova R, Akepati PR, Wormald MR, McElvaney OJ, Shutchaidat V, Henry M, Meleady P, Keenan J, Liberti DC, Kotton DN, Rudd PM, Wilson AA, McElvaney NG. Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity. J Immunol. 2019 Apr 15; 202(8):2240-2253.View Related Profiles. PMID: 30796179.
  2. Reeves EP, O'Dwyer CA, Dunlea DM, Wormald MR, Hawkins P, Alfares M, Kotton DN, Rowe SM, Wilson AA, McElvaney NG. Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med. 2018 Oct 15; 198(8):1099-1102.View Related Profiles. PMID: 30011228.
  3. Kaserman JE, Wilson AA. Patient-Derived Induced Pluripotent Stem Cells for Alpha-1 Antitrypsin Deficiency Disease Modeling and Therapeutic Discovery. Chronic Obstr Pulm Dis. 2018 Sep 15; 5(4):258-266.View Related Profiles. PMID: 30723783.
  4. Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Sep; 25(3):148-155.View Related Profiles. PMID: 30032658.
  5. Segeritz CP, Rashid ST, de Brito MC, Serra MP, Ordonez A, Morell CM, Kaserman JE, Madrigal P, Hannan NRF, Gatto L, Tan L, Wilson AA, Lilley K, Marciniak SJ, Gooptu B, Lomas DA, Vallier L. hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in a1-antitrypsin deficiency. J Hepatol. 2018 Oct; 69(4):851-860.View Related Profiles. PMID: 29879455.
  6. Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, Wilson AA, Kotton DN, Quinton LJ, Jones MR, Pelton SI, Mizgerd JP. Capacity of Pneumococci to Activate Macrophage Nuclear Factor ?B: Influence on Necroptosis and Pneumonia Severity. J Infect Dis. 2017 Aug 15; 216(4):425-435.View Related Profiles. PMID: 28368460; DOI: 10.1093/infdis/jix159;.
  7. Pastore N, Attanasio S, Granese B, Castello R, Teckman J, Wilson AA, Ballabio A, Brunetti-Pierri N. Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin. Hepatology. 2017 Jun; 65(6):1865-1874. PMID: 28073160; DOI: 10.1002/hep.29035;.
  8. Kaserman JE, Wilson AA. Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) to a Hepatic Lineage. Methods Mol Biol. 2017; 1639:151-160.View Related Profiles. PMID: 28752455.
  9. Payne JG, Takahashi A, Higgins MI, Porter EL, Suki B, Balazs A, Wilson AA. Multilineage transduction of resident lung cells in vivo by AAV2/8 for a1-antitrypsin gene therapy. Mol Ther Methods Clin Dev. 2016; 3:16042. PMID: 27408904; DOI: 10.1038/mtm.2016.42;.
  10. Tafaleng EN, Chakraborty S, Han B, Hale P, Wu W, Soto-Gutierrez A, Feghali-Bostwick CA, Wilson AA, Kotton DN, Nagaya M, Strom SC, Roy-Chowdhury J, Stolz DB, Perlmutter DH, Fox IJ. Induced pluripotent stem cells model personalized variations in liver disease resulting from a1-antitrypsin deficiency. Hepatology. 2015 Jul; 62(1):147-57.View Related Profiles. PMID: 25690322; PMCID: PMC4482790; DOI: 10.1002/hep.27753;.
Showing 10 of 20 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 20 publications over 11 distinct years, with a maximum of 4 publications in 2018

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

alpha-1 antitrypsin
gene therapy
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map

Wilson's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department